New mechanistic insights into how the gut metabolite urolithin A extends lifespan and prevents AD

关于肠道代谢物尿石素 A 如何延长寿命和预防 AD 的新机制见解

基本信息

项目摘要

PROJECT SUMMARY/ABSTRACT The parent award proposes to assess the potential neuroprotective effects of the gut metabolite urolithin A (UA) in the 3xAD Tg model of Alzheimer’s disease (AD). Aim 3 of the grant centers on the hypothesis that reductions in age-related gut microbiota involved in the production of UA from its dietary precursor ellagic acid may contribute to increased neuropathology associated with the 3xAD model and can be prevented by restoration of a more youthful microbiome. In addition to its direct impact on neurons (the subject of the parent grant), UA potentially may also have indirect effects via its ability to maintain gut integrity and function which can have ‘knock on’ effects on neuronal integrity via the gut-brain axis. In order to get a better handle on potential mechanisms that may underlie gut inflammation and influence the development of AD-related neuropathology in these mice, we initiated a collaboration with Dr. Dan Winer at the Buck, an expert on the role of the adaptive immune system in controlling metabolic tissue inflammation. Bacterial profiling was performed and revealed a clear difference in the levels of pro-inflammatory bacteria in the AD mouse colon, coinciding with a striking enrichment in the level of CD4+Tbet+ (Th1) immune cell populations previously linked to reduced gut barrier function and dysbiosis. Additional studies as part of the funded parent grant demonstrated that UA-fed 3xAD mice show significant reductions in Aß neuropathology and improvement in behavioral deficits. As postulated in the original grant, this may be in part due to direct effects on neuronal cells in the CNS. However, it may also involve the compound’s ability to maintain gut integrity and function and reduce gut inflammation. The purpose of this supplement is to provide us with funds to allow us to determine whether UA’s neuroprotective effects are due in part to its ability to influence gut health.
项目摘要/摘要 父母奖的提案,以评估肠道代谢物尿石素A的潜在神经保护作用 (UA)在阿尔茨海默氏病(AD)的3XAD TG模型中。授予中心的目标3关于以下假设 与年龄相关的肠道菌群的减少参与UA产生的饮食前体胆酸产生 可能有助于增加与3XAD模型相关的神经病理学,并且可以通过 恢复更年轻的微生物组。 除了对神经元的直接影响(父母赠款的主题)外,UA还可能有 通过维持肠道完整性和功能的能力间接影响,这可以“敲击”对 通过肠脑轴神经元完整性。为了更好地处理可能的潜在机制 肠道注射并影响这些小鼠中与广告相关的神经病理学的发展,我们 与Dan Winer博士在Buck的合作中启动,该专家是适应性免疫系统在 控制代谢组织炎症。进行了细菌分析,并揭示了明显的差异 AD小鼠结肠中促炎细菌的水平,与该水平的罢工富集一致 CD4+ TBET+(TH1)的免疫细胞群体先前与肠道屏障功能降低和营养不良有关。 作为资助的父母赠款的一部分的其他研究表明,UA喂养的3XAD小鼠显示出显着的 Aß神经病理学的减少和行为定义的改善。如原始赠款中发布的 这可能部分是由于对中枢神经系统中神经元细胞的直接影响。但是,它也可能涉及 化合物保持肠道完整性和功能并减少肠道注射的能力。这个目的 补充是为我们提供资金,以允许我们确定UA的神经保护作用是否应到期 部分影响其影响肠道健康的能力。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

暂无数据

数据更新时间:2024-06-01

Julie Kay Andersen的其他基金

Novel mitochondria-to-lysosome crosstalk contributes to lysosomal dysfunction during aging
新型线粒体与溶酶体串扰导致衰老过程中溶酶体功能障碍
  • 批准号:
    10723050
    10723050
  • 财政年份:
    2023
  • 资助金额:
    $ 46.15万
    $ 46.15万
  • 项目类别:
Neuronal FXR as a potential therapeutic target for Alzheimer's disease
神经元 FXR 作为阿尔茨海默病的潜在治疗靶点
  • 批准号:
    10374862
    10374862
  • 财政年份:
    2020
  • 资助金额:
    $ 46.15万
    $ 46.15万
  • 项目类别:
Cellular senescence and Alzheimer's disease
细胞衰老和阿尔茨海默病
  • 批准号:
    10044328
    10044328
  • 财政年份:
    2020
  • 资助金额:
    $ 46.15万
    $ 46.15万
  • 项目类别:
Neuronal FXR as a potential therapeutic target for Alzheimer's disease
神经元 FXR 作为阿尔茨海默病的潜在治疗靶点
  • 批准号:
    10600989
    10600989
  • 财政年份:
    2020
  • 资助金额:
    $ 46.15万
    $ 46.15万
  • 项目类别:
Research Development Core
研究开发核心
  • 批准号:
    10649616
    10649616
  • 财政年份:
    2020
  • 资助金额:
    $ 46.15万
    $ 46.15万
  • 项目类别:
Environmental exposure and astrocytic senescence: novel link to PD?
环境暴露和星形细胞衰老:与 PD 的新联系?
  • 批准号:
    8758627
    8758627
  • 财政年份:
    2014
  • 资助金额:
    $ 46.15万
    $ 46.15万
  • 项目类别:
2011 Oxidative Stress and Disease Gordon Research Conference
2011 氧化应激与疾病戈登研究会议
  • 批准号:
    8045654
    8045654
  • 财政年份:
    2010
  • 资助金额:
    $ 46.15万
    $ 46.15万
  • 项目类别:
2011 Oxidative Stress and Disease Gordon Research Conference
2011 氧化应激与疾病戈登研究会议
  • 批准号:
    8209520
    8209520
  • 财政年份:
    2010
  • 资助金额:
    $ 46.15万
    $ 46.15万
  • 项目类别:
2011 Oxidative Stress and Disease Gordon Research Conference
2011 氧化应激与疾病戈登研究会议
  • 批准号:
    8214198
    8214198
  • 财政年份:
    2010
  • 资助金额:
    $ 46.15万
    $ 46.15万
  • 项目类别:
Pharmacology of Lifespan Extension
延长寿命的药理学
  • 批准号:
    9521330
    9521330
  • 财政年份:
    2008
  • 资助金额:
    $ 46.15万
    $ 46.15万
  • 项目类别:

相似海外基金

Contribution of Vitamin D Deficiency to Pathological Progression in Models of Cerebral Hypoperfusion
维生素 D 缺乏对脑低灌注模型病理进展的影响
  • 批准号:
    10725358
    10725358
  • 财政年份:
    2023
  • 资助金额:
    $ 46.15万
    $ 46.15万
  • 项目类别:
Role of meningeal lymphatic vasculature in neuroimmune communication development
脑膜淋巴管系统在神经免疫通讯发育中的作用
  • 批准号:
    10566682
    10566682
  • 财政年份:
    2023
  • 资助金额:
    $ 46.15万
    $ 46.15万
  • 项目类别:
Infectious history as a determinant of age-related inflammation in Alzheimers disease
感染史是阿尔茨海默病年龄相关炎症的决定因素
  • 批准号:
    10663042
    10663042
  • 财政年份:
    2023
  • 资助金额:
    $ 46.15万
    $ 46.15万
  • 项目类别:
ADRD spousal caregivers, loneliness, & immune dysregulation: Real-Time, real-world intervention targets
ADRD 配偶照顾者、孤独、
  • 批准号:
    10651524
    10651524
  • 财政年份:
    2023
  • 资助金额:
    $ 46.15万
    $ 46.15万
  • 项目类别:
2023 Phagocytes Gordon Research Conference and Gordon Research Seminar
2023吞噬细胞戈登研究大会暨戈登研究研讨会
  • 批准号:
    10683594
    10683594
  • 财政年份:
    2023
  • 资助金额:
    $ 46.15万
    $ 46.15万
  • 项目类别: